Dr. T. SUJIT | Expert Consultant Radiation Oncologist

Academic Excellence
Awards and Recognitions

Dr. T. Sujit is the HoD, Department of Radiation Oncology and Consultant Radiation Oncologist at G. Viswanathan Hospital, Singarathope, Trichy. He is a vital part of the Comprehensive Cancer Care Network (CCCN) team that takes care of the entire Oncology department at GVN Hospital
He completed his MBBS from Stanley Medical College, Chennai. He completed his DMRT from the prestigious Barnard Institute of Radiology (BIR) at Madras Medical College and General Hospital, Chennai. Subsequent to this, he trained under the DNB programme for 2 years at Valavadi Narayanaswamy Cancer Centre, one of the oldest and renowned cancer centres in the country, at G. Kuppuswamy Naidu Memorial Hospital, Coimbatore. He later served as Assistant Radiation Oncologist at the same centre till 2011.
In 2011, he was invited to join Thanjavur Cancer Centre, Thanjavur, which was then a fledgling set up. He was instrumental in bringing up the department to AERB standards and helped the centre achieve the necessary requirements to be empanelled under government health insurance schemes, which was a first in the entire Thanjavur and surrounding districts
In 2013, he joined G.Viswanathan Hospital, Singarathope, Trichy and has taken the centre to the forefront of fighting cancer using state of the art equipment and techniques.
He is a part of the dynamic CCCN team consisting of two surgical oncologists, one medical oncologist and himself as the radiation oncologist. As part of CCCN’s childhood cancer support group, SACHICAN, he takes pride in providing the best radiation treatment to childhood cancer patients. He is skilled in and specializes in conformal and advanced radiation therapy techniques.
As part of CCCN’s academic activities, he is an active member of Oncoclub and conducts regular CME programmes for the medical community of Trichy and surrounding districts.

DNB THESIS : Thyroid dysfunction in patients treated with Radiotherapy / Chemo-Radiotherapy for non- thyroid head & neck cancers.

WORKSHOPS ATTENDED

Workshop and Hands-on Training on High Precision Radiation at Apollo Speciality Hospitals , Chennai, January 2004.
Workshop on Bench to Bedside held at Kidwai Memorial Institute of Oncology, Bangalore, October 2004.
Investigator's Meet for a Clinical trial on Deforolimus at Prague, Czech Republic - “A randomized phase II trial of deforolimus (AP 23573; MK – 8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy.”

PAPERS PRESENTED

Proffered paper in the 23rd State Annual AROI Conference Tamil Nadu & Pondicherry chapter, 2008 and was awarded the BEST PAPER PRIZE for the paper titled “Thyroid dysfunction in patients treated with radiotherapy/ chemo-radiotherapy for non-thyroid head & neck cancers.”
Proffered paper in 29th Annual National AROICON 2007 ( Association of Radiation Oncologists of India Conference ) titled “Thyroid dysfunction in patients treated with Radiotherapy / Chemo- Radiotherapy for non-thyroid head & neck cancers.”
Proffered paper in 19th State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2003 (Association of Radiation Oncologists of India Conference ) titled “ Rare case presentation – A case of solitary plasmacytoma of occipital bone .”
Poster presentation in 24th National AROICON 2002 ( Association of Radiation Oncologists of India Conference ).

CONFERENCES ATTENDED

24th National AROICON 2002 ( Association of Radiation Oncologists of India Conference ).
26th National AROICON 2004 ( Association of Radiation Oncologists of India Conference ).
29th National AROICON 2007 ( Association of Radiation Oncologists of India Conference ).
11th Biennial Conference of Indian Society of Oncology and 13th Biennial Conference of Indian Society of Medical & Paediatric Oncology , October 2004.
Multimodality Head & Neck Cancer Care symposium at Tata Memorial Hospital, Mumbai, Dec 2005.
18th State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2002
19th State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2003
20th State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2004
21st State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2005
23rd State Annual AROI Conference (Tamil Nadu & Pondicherry chapter) 2008
10th Annual Conference on Medical Physics and Radiation Safety, 2003.
RGCON 2010 at Rajiv Gandhi Cancer Institute, New Delhi 26th - 28th March 2010

INVOLVEMENT IN CONFERENCES & CME PROGRAMMES

Organising member , Oncoclub , July 2013; Focus - Radiology in Oncology
Organising Member & Faculty, HOPE 2013, Trichy
Organising member , Oncoclub , Feb 2014 ; Focus - Approach to Head and Neck Cancers
Organising member , Oncoclub , Aug 2014; Focus - Neuro-Oncology
Organising Member & Faculty, BRECON 2013, Trichy.
Organising Member & Faculty, BRECON 2014, Trichy.
Organising Member & Faculty, BRECON 2015, Trichy.
Organising Member & Faculty, 8 th Tamilnadu Puducherry Padiatric Oncology Group(TPPOG) meet Feb,2016,Trichy
Panelist at ICON Sept 2015 held at Coimbatore : Panel Discussion : Addressing Brain metastasis in Breast Ca & Lung cancer Is there a change in approach ? CLINICAL TRIALS : Gained experience as Clinical Trial Co-ordinator in following trials 1. Pharmanet STUDY NAME: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection Multikine® Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemoradiotherapy) in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity / Soft Palate Versus Standard of Care Only. 2. Piramal ( SPARK ) An open label,multi center phase II study of Selective Cyclin Dependent Kinase InhibitorP276- 00 In Combination with Radiation In Subjects with Recurrent and/or Locally advanced Squamous Cell Carcinoma of Head and Neck (P276- 00/31/08) 3. Sanofi Aventis ; CRO - Icon A Mulitnational,Randomized,double- blind,placebo controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of Venous Thromboembolism(VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy(protocol EFC6521). 4. GeneMedix plc ; CRO - Reliance CRO Safety and Efficacy of Recombinant Human Granulocyte-colony Stimulating factor GCSF (ReliGrast tm or Neupogen R) in Patients with Chemotherapy induced Neutropenia. 5. Alder Biopharmaceuticals ; CRO- Veeda Oncology A Phase II Study to Determine the Safety, Efficacy and Pharmacokinetics of multiple Intravenous Doses of ALD518 80, 160 mg Versus Placebo Administrated to Patients with Non-small Cell Lung cancer- Related Fatigue and Cachexia. 6. Ariad pharmaceuticals ; CRO - Medpace A randomized phase II trial of deforolimus (AP 23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy. 7. Glaxosmithkline pharmaceuticals limited. A Phase III study of Erbb2 Positive Advanced Or Metastatic Gastric Or Esophageal Or Gastroesophageal junction Adenocarcenoma Treated With Capecitabine Plus Oxaliplatin With Or Without Lapatinib.”

Name	Dr. T. SUJIT Consultant Radiation Oncologist
Department	Radiation Oncology
Degree	MBBS, DMRT, DNB.,
Extension Number	0422 - 2227533